In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide, the active ingredient in Ozempic and Wegovy.